ABOUT US

NEWS

INVESTOR RELATIONS

简 繁 EN
Essex-Bio Group
简 繁 EN
简 繁 EN
COMPANY NEWS
Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022”
2022.08.15
EssexBio awarded “2021 China Pharmaceutical Industry Top 100 Series List” and “2022 China Pharmaceutical Brands List”
2022.07.15
Time
Last 7 days Last 30 days The last six months
Date
Title
2022-08-24
Essex Bio-Technology (1061.HK) 2022 Interim Results at a Glance
2022-08-23
Essex Bio-Technology Announces 2022 Interim Financial Results
2022-08-15
Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022”
2022-07-15
EssexBio awarded “2021 China Pharmaceutical Industry Top 100 Series List” and “2022 China Pharmaceutical Brands List”
2022-05-07
Essex Bio-Technology attends the 2022 GRC-FGF Conference, with two cutting-edge scientific research accepted by GRC
2022-04-29
Essex Bio-Technology Announces Upcoming Presentation at ARVO 2022 Annual Meeting
2022-04-19
First Patient in Australia Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases
2022-04-08
First Patient Dosed in a Global Multi-Centre Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for treatment of Ophthalmic Diseases in the EU
< 1 2 3 4 5 6 7 
Essex-Bio Group
BIOTECH
HEALTHTECH
Links
Wuhan Adv.Dental Bio-Technology
UNO Medical Group
Antikor Biopharma
Mitotech S.A.
Henlius
Humacyte
Copyright © 2020 Essex Bio-Technology Limited All Rights Reserved.
Disclaimer | Privacy Policy
粤公网安备 44049102496184号粤ICP备09032349号-1 深圳网站建设 深圳联雅
This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.
ACCEPT